» Articles » PMID: 39852786

Distinct Neutralising and Complement-Fixing Antibody Responses Can Be Induced to the Same Antigen in Haemodialysis Patients After Immunisation with Different Vaccine Platforms

Abstract

: Generalised immune dysfunction in chronic kidney disease, especially in patients requiring haemodialysis (HD), significantly enhances the risk of severe infections. Vaccine-induced immunity is typically reduced in HD populations. The SARS-CoV-2 pandemic provided an opportunity to examine the magnitude and functionality of antibody responses in HD patients to a previously unencountered antigen-Spike (S)-glycoprotein-after vaccination with different vaccine platforms (viral vector (VV); mRNA (mRV)). We compared the total and functional anti-S antibody responses (cross-variant neutralisation and complement binding) in 187 HD patients and 43 healthy controls 21-28 days after serial immunisation. : After 2 doses of the same vaccine, HD patients had anti-S antibody levels and a complement binding capacity comparable to controls. However, 2 doses of mRV induced greater polyfunctional antibody responses than VV (defined by the presence of both complement binding and cross-variant neutralisation activity). Interestingly, an mRV boost after 2 doses of VV significantly enhanced antibody functionality in HD patients without a prior history of SARS-CoV-2 infection. : HD patients can generate near-normal, functional antigen-specific antibody responses following serial vaccination to a novel antigen. Encouragingly, exploiting immunological memory by using mRNA vaccines and boosting may improve the success of vaccination strategies in this vulnerable patient population.

References
1.
Wall N, Godlee A, Geh D, Jones C, Faustini S, Harvey R . Latent Cytomegalovirus Infection and Previous Capsular Polysaccharide Vaccination Predict Poor Vaccine Responses in Older Adults, Independent of Chronic Kidney Disease. Clin Infect Dis. 2021; 73(4):e880-e889. PMC: 8366832. DOI: 10.1093/cid/ciab078. View

2.
Tabinor M, Crowley L, Godlee A, Flanagan D, Rashid R, Baharani J . End-stage kidney disease patients from ethnic minorities and mortality in coronavirus disease 2019. Hemodial Int. 2021; 26(1):83-93. PMC: 8444789. DOI: 10.1111/hdi.12976. View

3.
Hauser A, Stinghen A, Kato S, Bucharles S, Aita C, Yuzawa Y . Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int. 2008; 28 Suppl 3:S183-7. View

4.
Barnes E, Goodyear C, Willicombe M, Gaskell C, Siebert S, I de Silva T . SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat Med. 2023; 29(7):1760-1774. PMC: 10353927. DOI: 10.1038/s41591-023-02414-4. View

5.
Ashby D, Caplin B, Corbett R, Asgari E, Kumar N, Sarnowski A . Severity of COVID-19 after Vaccination among Hemodialysis Patients: An Observational Cohort Study. Clin J Am Soc Nephrol. 2022; 17(6):843-850. PMC: 9269655. DOI: 10.2215/CJN.16621221. View